NIVF Stock Analysis: Buy, Sell, or Hold?
NIVF - NewGenIvf Group Limited Class A ordinary shares
$1.31
-0.18 (-12.08%)
▼
5d:
+152.55%
30d:
+91.24%
90d:
-38.5%
WAIT
LOW Confidence
Analysis Updated: Jul 7, 2026 12:00 AM ET
Earnings: Jun 30, 2026
0d
Get Alerted When NIVF Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
1 traders called NIVF this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: NIVF is 57.8% above its trading range ($0.83). Market expects -30.9% annual growth, but current price leaves little margin for error. While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: NIVF is 57.8% above its trading range ($0.83). Market expects -30.9% annual growth, but current price leaves little margin for error. While momentum could continue, risk/reward favors waiting for a pullback.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$10.91
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$6.78
80.7% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 0.2x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: NIVF is currently trading at $1.31, which is considered oversold relative to its 30-day fair value range of $0.52 to $0.83. From a valuation perspective, the stock is trading at a discount (Forward PE: 0.1) compared to its historical average (0.2). Remarkably, the market is currently pricing in an annual earnings decline of 30.9% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, NIVF is in a uptrend. The price is approaching resistance at $1.20. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. Short-term momentum is weak, with the stock down 12.1% recently.
Market Sentiment: NIVF has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $42.36 (+3133.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, NIVF is in a uptrend. The price is approaching resistance at $1.20. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. Short-term momentum is weak, with the stock down 12.1% recently.
Market Sentiment: NIVF has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $42.36 (+3133.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.52 -
$0.83
Company Quality Score
48/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
85.7%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-12.1%)
- BULLISH: Trading 3133.6% below Wall St target ($42.36)
- WARNING: Recommendation downgraded due to 57.8% overvaluation
Trading Range Analysis
30-Day Trading Range
$0.52 -
$0.83
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.47
Resistance Level
$1.20
Current Trend
Uptrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
0.05
Wall Street Target
$42.36
(+3133.6%)
Revenue Growth (YoY)
11.9%
Profit Margin
209.0%
Valuation Discount vs History
-30.9% cheaper
PE vs Historical
0.1 vs 0.2
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-30.9%
(market-implied from PE analysis)
1-Year Target
$1.18
(-10%)
2-Year Target
$1.06
(-19%)
3-Year Target
$0.95
(-27%)
3-Yr Target (if PE normalizes)
(PE: 0→0)
$4.09
(+212%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 97.0%)
$2059.68
(+157128%)
Base:
(SPY PE: 0.0, Growth: 97.0%)
$4.42
(+238%)
Bear:
(PE: 0.0, Growth: 97.0%)
$3.76
(+187%)
📈
Valuation based on Current Earnings
Trailing PE: 0.01 | Current EPS (TTM): $117.02
Bull Case
$0.82
(-38%)
Analyst growth -50.0%, PE expands to 0.0
Base Case
$0.74
(-43%)
Market implied -50.0%, PE stable at 0.0
Bear Case
$1.01
(-23%)
Severe decline -20.0%, PE contracts to 0.0
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 0.0 to 0.2
Stabilization Target:
$5.60
(+327.8%)
PE Expansion Potential:
+327.8%
Share & Embed Analysis
Last updated: July 07, 2026 10:19 PM ET
Data refreshes hourly during market hours. Next update: 11:19 PM
Data refreshes hourly during market hours. Next update: 11:19 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NIVF showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Care Facilities Stocks
Top-rated stocks in Medical Care Facilities by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
THC
Tenet Healthcare Corpora… |
STRONG BUY
22 analysts |
$243 | 58 HOLD |
|
HCA
HCA Healthcare, Inc. |
BUY
25 analysts |
$500 | 67 BUY |
|
EHC
Encompass Health Corp |
STRONG BUY
12 analysts |
$141 | 58 HOLD |
|
CMPS
Compass Pathways Plc |
STRONG BUY
11 analysts |
$22 | 52 HOLD |
|
OPCH
Option Care Health Inc |
STRONG BUY
10 analysts |
$29 | 62 BUY |
